Inhibition of SPAK–NKCC1 complex not only preserved the barrier integrity, but also attenuated immune cell infiltration, emerging SPAK–NKCC1 signaling cascade as a therapeutic target for attenuating ChP dysfunction and brain inflammation after stroke. The gene discussed is STK39; the disease is stroke disorder.